Ligand ID: LPR


Drugbank ID:
DB00722
(Lisinopril)


Indication:
For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Get human targets for LPR in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'LPR'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		1uk4 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLU B 290
HIS B 172
HIS B 163
GLU B 166
LYS A   3
1.77A18.01
None
None
ATO  B2006 ( 4.6A)
ATO  B2006 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		1uk4 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
SER B  94
THR B  35
PHE B 159
0.83A19.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		1x7q HLA, A-11
(Homo
sapiens)		3 / 3
ALA A  69
THR A  73
PHE A  36
1.40A18.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		1x7q HLA, A-11
(Homo
sapiens)		5 / 12
GLN A  62
GLU A  55
TYR A   7
VAL A  34
TYR A  59
1.52A19.38
SO4  A4003 (-3.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		1xak ORF7A ACCESSORY
PROTEIN
(SARSr-CoV)		3 / 3
ALA A  40
THR A  13
PHE A  31
1.04A10.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		1yo4 HYPOTHETICAL PROTEIN
X4
(SARSr-CoV)		3 / 3
ALA A  40
THR A  13
PHE A  31
1.14A10.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		5 / 12
HIS D 227
THR D 239
HIS D 268
GLU D 246
HIS D 276
1.52A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		3 / 3
ALA G  59
THR E  73
PHE G  11
1.41A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		4 / 4
SER A 140
VAL A 156
PHE A 117
VAL A  96
1.78A15.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		5 / 12
HIS C  46
THR C  58
HIS C  87
GLU C  65
HIS C  95
1.49A15.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
SER A 116
THR A 169
PHE A 128
1.00A19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ALA A 150
THR A  91
PHE A  80
1.46A19.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 4
SER B 246
VAL B 301
PHE B 305
VAL B 117
1.70A19.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		3 / 3
ALA P   9
THR P  39
PHE N  16
1.64A13.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
SER A  94
THR A  35
PHE A 159
1.21A19.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ALA A 590
THR A 594
PHE A 615
1.65A12.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		2k87 NSP3 OF REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
ALA A  92
THR A  94
PHE A  54
1.02A11.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		2kqw NSP3
(SARSr-CoV)		5 / 12
THR A 140
GLU A 139
HIS A 173
VAL A 161
TYR A 152
1.79A14.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		2w2g NSP3
(SARSr-CoV)		3 / 3
ALA A 590
THR A 594
PHE A 615
1.62A18.63
None
SO4  A1653 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		3bgf F26G19 FAB
(Mus
musculus)		3 / 3
SER L  93
THR H  58
PHE H  63
1.30A16.01
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 4
SER B 124
VAL B 172
PHE B 504
VAL B 343
1.57A42.83
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
1.02A42.51
 ZN  B 901 (-3.8A)
ZN  B 901 (-3.3A)
ZN  B 901 (-3.8A)
ZN  B 901 (-2.8A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		7 / 12
THR B 371
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
0.96A36.20
None
ZN  B 901 (-3.8A)
ZN  B 901 (-3.3A)
ZN  B 901 (-3.8A)
ZN  B 901 (-2.8A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_A_LPRA705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
1.00A42.51
 ZN  B 901 (-3.8A)
ZN  B 901 (-3.3A)
ZN  B 901 (-3.8A)
ZN  B 901 (-2.8A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		7 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
PHE B 274
HIS B 505
TYR B 515
1.30A42.83
 ZN  B 901 (-3.8A)
ZN  B 901 (-3.3A)
ZN  B 901 (-3.8A)
ZN  B 901 (-2.8A)
None
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
1.13A35.96
 ZN  B 901 (-4.4A)
ZN  B 901 (-3.3A)
ZN  B 901 (-4.0A)
ZN  B 901 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		3e9s NSP3
(SARSr-CoV)		4 / 4
SER A 246
VAL A 301
PHE A 305
VAL A 117
1.69A19.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		3e9s NSP3
(SARSr-CoV)		3 / 3
SER A 116
THR A 169
PHE A 128
1.10A19.41
OCS  A 112 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3e9s NSP3
(SARSr-CoV)		3 / 3
ALA A 150
THR A  91
PHE A  80
1.47A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3ee7 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
ALA D  15
THR D  24
PHE D  56
1.44A11.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
SER A  94
THR A  35
PHE A 159
1.03A20.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3i6l HLA, A-24
(Homo
sapiens)		3 / 3
ALA D  69
THR D  73
PHE D  36
1.47A17.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		3mj5 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
SER B 116
THR B 169
PHE B 128
1.03A19.57
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		3 / 3
SER A 105
THR A  78
PHE A  32
1.04A36.33
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
1.33A36.33
 ZN  B 901 (-3.8A)
ZN  B 901 (-3.6A)
ZN  B 901 (-3.7A)
ZN  B 901 (-2.2A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		7 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
PHE B 274
HIS B 505
TYR B 515
1.34A42.86
 ZN  B 901 (-3.9A)
ZN  B 901 (-3.6A)
ZN  B 901 (-4.1A)
ZN  B 901 (-2.6A)
None
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 4
SER B 124
VAL B 172
PHE B 504
VAL B 343
1.45A42.86
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
THR A 371
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.65A36.67
None
ZN  A 901 (-3.5A)
ZN  A 901 (-3.7A)
ZN  A 901 (-3.5A)
ZN  A 901 (-2.8A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_A_LPRA705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
1.09A42.41
 ZN  B 901 (-3.9A)
ZN  B 901 (-3.6A)
ZN  B 901 (-4.1A)
ZN  B 901 (-2.6A)
None
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
HIS B 374
GLU B 375
HIS B 378
GLU B 402
HIS B 505
TYR B 515
1.13A42.41
 ZN  B 901 (-3.9A)
ZN  B 901 (-3.6A)
ZN  B 901 (-4.1A)
ZN  B 901 (-2.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		3to2 MHC CLASS I ANTIGEN
(Homo
sapiens)		3 / 3
ALA A  69
THR A  73
PHE A  36
1.47A18.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		4m0w REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
ALA A 150
THR A  91
PHE A  80
1.48A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		4m0w REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 4
SER A 246
VAL A 301
PHE A 305
VAL A 117
1.72A18.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		4m0w REPLICASE
POLYPROTEIN 1A
(SARSr)		3 / 3
SER A 116
THR A 169
PHE A 128
1.04A19.80
 NA  A 402 (-2.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		4mm3 PAPAIN-LIKE
PROTEINASE
(SARSr-CoV)		3 / 3
ALA B 150
THR B  91
PHE B  80
1.40A19.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		4 / 4
SER A 246
VAL A 301
PHE A 305
VAL A 117
1.65A19.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		3 / 3
ALA A 265
THR A 119
PHE A 312
1.30A19.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		3 / 3
SER A 167
THR A 172
PHE A 148
0.99A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5c5o 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
SER B  94
THR B  35
PHE B 159
1.23A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		3 / 3
ALA D  79
THR D  75
PHE D 286
1.39A21.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr)		3 / 3
SER B 448
THR B 522
PHE B 514
1.28A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ALA D 150
THR D  91
PHE D  80
1.36A18.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 4
SER D 246
VAL D 301
PHE D 305
VAL D 117
1.71A19.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
SER D 116
THR D 169
PHE D 128
1.06A19.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5ko3 ORF1A
(MERS-CoV)		3 / 3
SER A 167
THR A 172
PHE A 148
1.13A18.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 4
SER D 507
VAL D 312
PHE D 401
VAL D 405
1.73A21.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
SER A  46
THR A  24
PHE A  66
1.61A13.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
SER D 116
THR D 169
PHE D 128
0.99A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 4
SER D 246
VAL D 301
PHE D 305
VAL D 117
1.67A19.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ALA B 150
THR B  91
PHE B  80
1.47A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ALA A1037
THR A 856
PHE A 805
1.31A17.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5x4r S PROTEIN
(MERS-CoV)		3 / 3
ALA A 146
THR A 206
PHE A 313
1.33A18.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER A 173
THR A 148
PHE A  22
1.20A19.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5x59 S PROTEIN
(MERS-CoV)		3 / 3
SER B 426
THR B 574
PHE B 446
0.69A18.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5x59 S PROTEIN
(MERS-CoV)		3 / 3
ALA B 146
THR B 206
PHE B 313
1.33A17.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		3 / 3
SER B1003
THR B1009
PHE C1024
1.12A19.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER C1003
THR C1009
PHE B1024
1.06A19.20
SER  C1003 ( 0.0A)
THR  C1009 ( 0.8A)
PHE  B1024 ( 1.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
SER A 116
THR A 169
PHE A 128
1.09A19.31
 NA  A 403 (-3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		3 / 3
ALA A 150
THR A  91
PHE A  80
1.46A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		5y3q REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 4
SER A 246
VAL A 301
PHE A 305
VAL A 117
1.76A19.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER B1003
THR B1009
PHE A1024
0.89A19.20
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6acg ACE2
(Homo
sapiens)		5 / 12
HIS D 374
GLU D 375
HIS D 378
GLU D 402
TYR D 515
1.02A42.58
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_A_LPRA705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6acg ACE2
(Homo
sapiens)		5 / 12
HIS D 374
GLU D 375
HIS D 378
GLU D 402
TYR D 515
0.96A42.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
SER B 211
VAL B  66
PHE B  62
VAL B  40
1.64A19.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLN B1036
THR B 706
HIS B1046
GLU B 707
VAL B 763
1.55A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ALA C 250
THR C 247
PHE C 253
1.20A17.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
ALA B 422
THR B 363
PHE B 334
1.55A18.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
SER C  35
THR C  67
PHE C 231
1.19A19.16
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_A_LPRA705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6cs2 ACE2
(Homo
sapiens)		5 / 12
ALA D 348
GLU D 375
HIS D 374
GLU D 402
HIS D 401
1.38A42.35
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6cs2 ACE2
(Homo
sapiens)		5 / 12
HIS D 374
GLU D 375
HIS D 378
GLU D 402
TYR D 515
1.54A42.35
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		6cs2 ACE2
(Homo
sapiens)		5 / 12
HIS D 374
GLU D 375
HIS D 378
GLU D 402
TYR D 515
1.51A42.83
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6cs2 ACE2
(Homo
sapiens)		5 / 12
THR D 347
GLU D 375
HIS D 374
GLU D 402
HIS D 401
1.41A36.13
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		6cs2 ACE2
(Homo
sapiens)		5 / 12
HIS D 374
GLU D 375
HIS D 378
GLU D 402
TYR D 515
1.46A36.44
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6lzg ACE2
(Homo
sapiens)		5 / 12
HIS A 345
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.47A42.67
None
ZN  A 704 (-3.3A)
ZN  A 704 ( 4.3A)
ZN  A 704 (-3.3A)
ZN  A 704 (-2.1A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6lzg ACE2
(Homo
sapiens)		6 / 12
HIS A 345
THR A 371
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.49A36.20
None
None
ZN  A 704 (-3.3A)
ZN  A 704 ( 4.3A)
ZN  A 704 (-3.3A)
ZN  A 704 (-2.1A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		6lzg ACE2
(Homo
sapiens)		5 / 12
HIS A 345
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.41A42.81
None
ZN  A 704 (-3.3A)
ZN  A 704 ( 4.3A)
ZN  A 704 (-3.3A)
ZN  A 704 (-2.1A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		6lzg ACE2
(Homo
sapiens)		5 / 12
HIS A 345
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.40A35.96
None
ZN  A 704 (-3.3A)
ZN  A 704 ( 4.3A)
ZN  A 704 (-3.3A)
ZN  A 704 (-2.1A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6m0j ACE2
(Homo
sapiens)		6 / 12
HIS A 345
THR A 371
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.67A36.67
None
None
ZN  A 901 (-3.5A)
ZN  A 901 (-3.9A)
ZN  A 901 (-3.5A)
ZN  A 901 (-2.4A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		6m0j ACE2
(Homo
sapiens)		5 / 12
HIS A 345
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.67A36.33
None
ZN  A 901 (-3.5A)
ZN  A 901 (-3.9A)
ZN  A 901 (-3.5A)
ZN  A 901 (-2.4A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		6m0j ACE2
(Homo
sapiens)		5 / 12
HIS A 345
HIS A 374
GLU A 375
HIS A 378
GLU A 402
0.66A42.83
None
ZN  A 901 (-3.5A)
ZN  A 901 (-3.9A)
ZN  A 901 (-3.5A)
ZN  A 901 (-2.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
SER A  46
THR A  24
PHE A  66
1.30A18.94
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1O86_A_LPRA702_1
(ANGIOTENSIN
CONVERTING ENZYME)		6m17 ACE2
(Homo
sapiens)		5 / 12
HIS B 345
HIS B 374
GLU B 375
HIS B 378
GLU B 402
0.64A36.78
None
ZN  B 914 (-3.4A)
ZN  B 914 (-4.2A)
ZN  B 914 (-3.5A)
ZN  B 914 (-2.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		3 / 3
ALA C 282
THR C 121
PHE C 276
1.38A22.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_1
(ANGIOTENSIN
CONVERTING ENZYME)		6m18 ACE2
(Homo
sapiens)		5 / 12
HIS B 345
HIS B 374
GLU B 375
HIS B 378
GLU B 402
0.65A28.97
None
None
ZN  B 914 (-3.4A)
ZN  B 914 ( 4.6A)
ZN  B 914 (-4.0A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_A_LPRA705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6m18 ACE2
(Homo
sapiens)		5 / 12
HIS B 345
HIS B 374
GLU B 375
HIS B 378
GLU B 402
0.66A35.10
None
None
ZN  B 914 (-3.4A)
ZN  B 914 ( 4.6A)
ZN  B 914 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6m18 ACE2
(Homo
sapiens)		6 / 12
HIS B 345
THR B 371
HIS B 374
GLU B 375
HIS B 378
GLU B 402
0.67A28.68
None
None
None
ZN  B 914 (-3.4A)
ZN  B 914 ( 4.6A)
ZN  B 914 (-4.0A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6m18 ACE2
(Homo
sapiens)		5 / 12
HIS D 345
HIS D 374
GLU D 375
HIS D 378
GLU D 402
0.76A35.10
None
None
ZN  D 914 (-3.4A)
ZN  D 914 ( 4.6A)
ZN  D 914 (-4.0A)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6m1d ACE2
(Homo
sapiens)		3 / 3
ALA B 304
THR B 362
PHE B 327
1.36A35.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
SER B 254
THR B 304
PHE B   3
1.37A18.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
SER B  46
THR B  24
PHE B  66
1.56A18.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		6m71 NSP12
(SARS-CoV-2)		4 / 4
SER A 778
VAL A 785
PHE A 753
VAL A 764
1.57A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6m71 NSP12
(SARS-CoV-2)		3 / 3
SER A 772
THR A 710
PHE A 745
1.16A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ALA A 130
THR A 141
PHE A  45
1.19A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		6m71 NSP12
(SARS-CoV-2)		4 / 4
SER A 692
VAL A 588
PHE A 480
VAL A 476
1.80A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ALA A 690
THR A 686
PHE A 480
1.21A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
SER A 500
VAL A 498
PHE A 416
VAL A 369
1.69A17.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		4 / 4
SER L  28
VAL L   2
PHE L  76
VAL L  56
1.55A15.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6nus NSP12
(SARSr-CoV)		3 / 3
ALA A 690
THR A 686
PHE A 480
1.18A20.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		6nus NSP12
(SARSr-CoV)		4 / 4
SER A 778
VAL A 785
PHE A 753
VAL A 764
1.64A20.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER C1021
THR C1027
PHE A1042
1.24A19.17
None
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2C6N_A_LPRA705_1
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6vw1 ACE2
(Homo
sapiens)		5 / 12
HIS A 345
HIS A 374
GLU A 375
HIS A 378
GLU A 402
1.07A42.67
None
None
ZN  A 704 ( 3.8A)
ZN  A 704 ( 4.6A)
ZN  A 704 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6vxs NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6vxs NSP3
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6vxs NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6vxs NSP3
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER B 875
THR B 881
PHE B 927
1.20A19.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ALA C 520
THR C 393
PHE C 562
1.42A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER C 875
THR C 881
PHE C 927
1.19A19.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 244
THR B 282
PHE B 269
1.09A18.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6w37 PROTEIN 7A
(SARS-CoV-2)		3 / 3
ALA A  40
THR A  13
PHE A  31
0.98A8.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
SER H 153
THR H 165
PHE L 118
1.64A13.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
SER H 180
THR H 183
PHE L 139
1.76A13.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
SER L 168
THR L 172
PHE H 166
1.64A13.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER C 383
THR H  31
PHE C 342
0.93A14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER A6927
THR A6880
PHE A7048
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER A6896
THR A6880
PHE A7003
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w61 NSP10
(SARS-CoV-2)		3 / 3
SER B4325
THR B4364
PHE B4342
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6w6y NSP3
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6w6y NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6w6y NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6w6y NSP3
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w75 NSP16
(SARS-CoV-2)		3 / 3
SER C6927
THR C6880
PHE C7048
1.53A13.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w75 NSP16
(SARS-CoV-2)		3 / 3
SER A6927
THR A6880
PHE A7048
1.54A13.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w75 NSP16
(SARS-CoV-2)		3 / 3
SER A6896
THR A6880
PHE A7003
1.56A13.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w75 NSP16
(SARS-CoV-2)		3 / 3
SER C6896
THR C6880
PHE C7003
1.57A13.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
ALA C 149
THR C  90
PHE C  79
1.45A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
SER C 103
THR C 119
PHE C 127
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
SER B 103
THR B 119
PHE B 127
1.39A
 CL  B 502 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
ALA A 149
THR A  90
PHE A  79
1.48A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
SER A 103
THR A 119
PHE A 127
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		3 / 3
ALA B 149
THR B  90
PHE B  79
1.40A18.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6wcf NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6wcf NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6wen NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6wen NSP3
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6wey NSP3
(SARS-CoV-2)		5 / 12
HIS A 249
THR A 261
HIS A 290
GLU A 268
HIS A 298
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6wey NSP3
(SARS-CoV-2)		5 / 12
HIS A 249
THR A 261
HIS A 290
GLU A 268
HIS A 298
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wjt NSP10
(SARS-CoV-2)		3 / 3
SER D4325
THR D4364
PHE D4342
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER A6927
THR A6880
PHE A7048
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER A6896
THR A6880
PHE A7003
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wjt NSP10
(SARS-CoV-2)		3 / 3
SER B4325
THR B4364
PHE B4342
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER C6896
THR C6880
PHE C7003
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER C6927
THR C6880
PHE C7048
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
SER A  78
THR D  57
PHE D  66
1.31A
None
ZN  A 201 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
SER C  78
THR B  57
PHE B  66
1.45A
None
ZN  C 201 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
SER D  78
THR C  54
PHE C  66
1.71A
None
MES  D 201 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
SER B  78
THR A  54
PHE A  66
1.74A
None
MES  B 201 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkq NSP16
(SARS-CoV-2)		3 / 3
SER A6896
THR A6880
PHE A7003
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkq NSP16
(SARS-CoV-2)		3 / 3
SER C6896
THR C6880
PHE C7003
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkq NSP10
(SARS-CoV-2)		3 / 3
SER B4325
THR B4364
PHE B4342
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkq NSP16
(SARS-CoV-2)		3 / 3
SER A6927
THR A6880
PHE A7048
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wkq NSP16
(SARS-CoV-2)		3 / 3
SER C6927
THR C6880
PHE C7048
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER A 244
THR A 282
PHE A 269
1.12A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 274
THR B 196
PHE B 204
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER A 274
THR A 196
PHE A 204
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 244
THR B 282
PHE B 269
1.12A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS D  45
THR D  57
HIS D  86
GLU D  64
HIS D  94
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
HIS D  45
THR D  57
HIS D  86
GLU D  64
HIS D  94
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wq3 NSP10
(SARS-CoV-2)		3 / 3
SER B4325
THR B4364
PHE B4342
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER A6927
THR A6880
PHE A7048
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		3 / 3
SER A6896
THR A6880
PHE A7003
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
SER A  46
THR A  24
PHE A  66
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		6wrh PEPTIDASE C16
(SARS-CoV-2)		3 / 3
ALA A 149
THR A  90
PHE A  79
1.50A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6wrh NSP3
(SARS-CoV-2)		3 / 3
SER A 103
THR A 119
PHE A 127
1.39A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6xez NSP12
(SARS-CoV-2)		3 / 3
SER A 692
THR A 586
PHE A 753
1.36A21.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER B 184
THR B 187
PHE C 145
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 4
ARG C  60
ALA C  57
SER C  58
TYR C  55
1.79A15.97
None
None
None
DMS  A 905 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER B 157
THR B 169
PHE C 124
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER L  62
THR A 385
PHE B  29
1.74A
MLI  B 303 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER A 371
THR B  31
PHE A 515
1.27A
DMS  A 901 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER A 383
THR B  31
PHE A 342
1.12A
DMS  A 905 (-3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 4
ARG C  60
ALA C  57
SER C  58
TYR C  55
1.79A15.97
None
None
None
DMS  A 905 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER H 157
THR H 169
PHE L 124
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER C 174
THR C 178
PHE B 170
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER C  62
THR E 385
PHE H  29
1.71A
MLI  B 303 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER E 371
THR H  31
PHE E 515
1.31A
DMS  E 901 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER A 530
THR A 523
PHE A 515
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER H 184
THR H 187
PHE L 145
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER L 174
THR L 178
PHE H 170
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER H 184
THR H 187
PHE L 145
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER E 383
THR H  31
PHE E 342
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6ym0 LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER L   7
THR L  78
PHE L  68
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER L 174
THR L 178
PHE H 170
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER H 157
THR H 169
PHE L 124
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER E 371
THR H  31
PHE E 515
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
SER H 184
THR H 187
PHE L 145
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
SER C 174
THR C 178
PHE B 170
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER E 371
THR H  31
PHE E 515
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
SER B 184
THR B 187
PHE C 145
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
SER B 157
THR B 169
PHE C 124
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
SER H 157
THR H 169
PHE L 124
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER A 371
THR B  31
PHE A 515
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
SER L 174
THR L 178
PHE H 170
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
SER A  46
THR A  24
PHE A  66
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS E  45
THR E  57
HIS E  86
GLU E  64
HIS E  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS D  45
THR D  57
HIS D  86
GLU D  64
HIS D  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS E  45
THR E  57
HIS E  86
GLU E  64
HIS E  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS D  45
THR D  57
HIS D  86
GLU D  64
HIS D  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS E  45
THR E  57
HIS E  86
GLU E  64
HIS E  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS E  45
THR E  57
HIS E  86
GLU E  64
HIS E  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS D  45
THR D  57
HIS D  86
GLU D  64
HIS D  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS D  45
THR D  57
HIS D  86
GLU D  64
HIS D  94
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS C  45
THR C  57
HIS C  86
GLU C  64
HIS C  94
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_A_LPRA801_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS A  45
THR A  57
HIS A  86
GLU A  64
HIS A  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1J36_B_LPRB802_1
(ANGIOTENSIN
CONVERTING ENZYME)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
HIS B  45
THR B  57
HIS B  86
GLU B  64
HIS B  94
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7btf NSP12
(SARS-CoV-2)		3 / 3
ALA A 923
THR A 929
PHE A 920
1.50A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7btf NSP12
(SARS-CoV-2)		3 / 3
SER A 692
THR A 586
PHE A 753
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		7btf NSP12
(SARS-CoV-2)		4 / 4
SER A 778
VAL A 785
PHE A 753
VAL A 764
1.60A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7btf NSP12
(SARS-CoV-2)		3 / 3
ALA A 690
THR A 686
PHE A 480
1.26A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7btf NSP12
(SARS-CoV-2)		3 / 3
SER A 564
THR A 531
PHE A 652
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7btf NSP12
(SARS-CoV-2)		3 / 3
SER A 772
THR A 710
PHE A 745
1.08A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7btf NSP12
(SARS-CoV-2)		3 / 3
ALA A 130
THR A 141
PHE A  45
1.11A20.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
SER A  46
THR A  24
PHE A  66
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
SER A   1
THR A 304
PHE A 219
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
SER A 254
THR A 304
PHE A   3
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ALA A 690
THR A 686
PHE A 480
1.17A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ALA A 130
THR A 141
PHE A  45
1.07A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv1 NSP12
(SARS-CoV-2)		4 / 4
SER A 692
VAL A 588
PHE A 480
VAL A 476
1.76A20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv1 NSP12
(SARS-CoV-2)		4 / 4
SER A 778
VAL A 785
PHE A 753
VAL A 764
1.45A20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
SER A 692
THR A 586
PHE A 753
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
SER A 772
THR A 710
PHE A 745
1.13A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X91_A_LPRA1615_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
SER A 692
THR A 586
PHE A 753
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 4
SER B 164
VAL B 167
PHE A 407
VAL A 405
1.72A15.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv2 NSP12
(SARS-CoV-2)		4 / 4
SER A 778
VAL A 785
PHE A 753
VAL A 764
1.55A20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ALA A 690
THR A 686
PHE A 480
1.19A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1O86_A_LPRA702_2
(ANGIOTENSIN
CONVERTING ENZYME)		7bv2 NSP12
(SARS-CoV-2)		4 / 4
SER A 692
VAL A 588
PHE A 480
VAL A 476
1.75A20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2C6N_B_LPRB705_2
(ANGIOTENSIN-CONVERTI
NG ENZYME, SOMATIC
ISOFORM)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ALA A 130
THR A 141
PHE A  45
1.13A20.90
None